Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glaucoma and Ocular Hypertension Clear all
Completed Phase 4 Interventional Results available

Rocklatan® Evaluation

NCT05283395
View directory record Official record
Conditions
Glaucoma
Interventions
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Mission Hills, California • Newport Beach, California • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 13, 2026, 7:12 PM EDT
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
View directory record Official record
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 13, 2026, 7:12 PM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

NCT05024695
View directory record Official record
Conditions
Glaucoma
Interventions
MINIject™ Implant
Device
Lead sponsor
iSTAR Medical
Industry
Eligibility
46 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
28
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

NCT03858894
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
13
States / cities
Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

NCT00515424
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332059
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bel Air, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

NCT00716859
View directory record Official record
Conditions
Glaucoma
Interventions
Timolol, latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
36 Weeks to 18 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 13, 2026, 7:12 PM EDT
Terminated Phase 2 Interventional

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 13, 2026, 7:12 PM EDT
Not listed Phase 4 Interventional

The Effect of Education on Patient Compliance

NCT00376974
View directory record Official record
Conditions
Glaucoma
Interventions
American Academy of Ophthalmology Glaucoma Educational Tape
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Oct 13, 2026, 7:12 PM EDT
Not listed Not applicable Interventional

Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG

NCT03761992
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Gingko Baloba, Placebo
Dietary Supplement · Other
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 13, 2026, 7:12 PM EDT
Terminated Not applicable Interventional Results available

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

NCT02928289
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Not applicable Interventional Results available

The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure

NCT02754570
View directory record Official record
Conditions
Glaucoma, Open-angle, Hypertension, Ocular
Interventions
Pilocarpine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 13, 2026, 7:12 PM EDT
Withdrawn Phase 4 Interventional

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

NCT04676126
View directory record Official record
Conditions
Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions
Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Not applicable Interventional

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

NCT02627352
View directory record Official record
Conditions
Glaucoma
Interventions
Micropulse Transscleral Cyclophotocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 13, 2026, 7:12 PM EDT
Completed No phase listed Observational

Evaluation of OCT Measurements

NCT01806402
View directory record Official record
Conditions
Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Interventions
Not listed
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Daly City, California • Petaluma, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of PER-001 in Participants With Open-Angle Glaucoma

NCT05822245
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Drug
Lead sponsor
Perfuse Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 13, 2026, 7:12 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

NCT06848946
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
Interventions
iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery
Combination Product · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 13, 2026, 7:12 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

NCT03875911
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma, Glaucoma, Open-Angle
Interventions
Mitomycin C
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Arcadia, California • Fountain Valley, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT03488550
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
ANX007
Biological
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 13, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT03657797
View directory record Official record
Conditions
Glaucoma, Open-Angle, Hypertension, Ocular
Interventions
NCX 470, Latanoprost 0.005%
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 13, 2026, 7:12 PM EDT
Completed No phase listed Observational Results available

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

NCT04872348
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Atlanta, Georgia • Wichita, Kansas • Bloomington, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 13, 2026, 7:12 PM EDT
Not listed No phase listed Observational

Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries

NCT03584958
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 13, 2026, 7:12 PM EDT